Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
331-01-002 / 331-01-002 ISMRM Abstract

Differential Vulnerability of Oxidative and Glycolytic Metabolism in ApoE and APP mouse models of Alzheimer’s disease

Primary: Neuro - Alzheimer's Disease
Secondary: Preclinical Animal & in vitro MR - Biology, Models, Methods
331-01-002 · Neuro Imaging and Metabolism · Monday, 11 May, 8:20 AM–10:10 AM · Roof Terrace
331-01-002 · Neuro Imaging and Metabolism · Monday, 11 May, 8:20 AM–10:10 AM · Roof Terrace
Keywords: Alzheimer's Disease Hyperpolarized 13C MRI Mitochondrial metabolism Brain energy metabolism Amyloid precursor protein (APP)
Accepted
Tamara Vasilkovska 1,2,3, Marina Radoul1,2, Yoshitaka Sei3, Lillie Bui3, Caroline Guglielmetti1,2, Yadong Huang3,4,5, Jeremy W Gordon1, Ken Nakamura3,4, Myriam Chaumeil1,2
1Department of Radiology and Biomedical Imaging, University Of California, San Francisco (UCSF), United States of America
2Physical Therapy & Rehabilitation Science, University Of California, San Francisco (UCSF), United States of America
3Gladstone Institutes, San Francisco, United States of America
4Department of Neurology, University Of California, San Francisco (UCSF), United States of America
5Department of Pathology, University Of California, San Francisco (UCSF), United States of America
Presenting Author: Tamara Vasilkovska

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Batra, R. et al. The landscape of metabolic brain alterations in Alzheimer’s disease. Alzheimers Dement 19, 980–998 (2023).
2. Ferreira, I. L., Resende, R., Ferreiro, E., Rego, A. C. & Pereira, C. F. Multiple defects in energy metabolism in Alzheimer’s disease. Curr. Drug Targets 11, 1193–1206 (2010).
3. Reiman, E. M. et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334, 752–758 (1996).
4. Wolf, A. B., Caselli, R. J., Reiman, E. M. & Valla, J. APOE and neuroenergetics: an emerging paradigm in Alzheimer’s disease. Neurobiol. Aging 34, 1007–1017 (2013).
5. Orr, A. L. et al. Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function. J Alzheimers Dis 68, 991–1011 (2019).
6. Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci USA 101, 284–289 (2004).

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/331-01-002